IP Library › Granted Patent US 9,434,760
Granted Patent B2
US 9,434,760 · App. 13/884,196 · Granted Sep 6, 2016

Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof

Inventors: Min Li (Ringoes, NJ); Hanbin Shan (Shanghai, CN); Yu Huang (Shanghai, CN); Zhedong Yuan (Shanghai, CN); Xiong Yu (Shanghai, CN)
Assignee: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
C07K5/0215A61K9/2054A61K9/2059A61K9/4858A61K9/4866A61K38/06A61K47/12A61K47/38C07D205/04C07D207/16C07D211/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,434,760
App. No.
13/884,196
Granted
Sep 6, 2016
Kind
B2
Abstract

Provided are a compound of formula (I), pharmaceutically acceptable salts thereof, preparation methods and applications thereof for inhibiting thrombin, and applications in the treatment and prevention of thrombin-mediated and thrombin-related diseases.

Claims (19)

1. A compound of formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof:

wherein:

A represents —SO 2 R 1 , —COR 1 , —R 2 COR 1 , or —R 2 CO 2 R 1 ;

wherein:

R 1 represents cycloalkyl, aryl, —R 3 -cycloalkyl, —R 3 -aryl, or —NR 4 R 5 ;

wherein cycloalkyl and aryl are substituted with 1 or 2 substituents selected from the group consisting of hydroxyl, carboxyl, halogen, C 1-4 alkyl, C 1-4 alkoxy, acyl, sulfonyl, sulfhydryl, alkylthio, cycloalkyl, heterocycloalkyl, amino, alkylamino, dialkylamino, cyano, ester group, trifluoromethyl, and CONH 2 ;

R 2 and R 3 represent unsubstituted C 1˜6 alkyl;

R 4 and R 5 represent independently H or unsubstituted C 1˜6 alkyl;

D represents

F represents —NH—(CH 2 ) m —R 6 ;

wherein:

m represents 1;

R 6 represents unsubstituted

G represents

wherein:

n represents 0; and

R 7 represents H.

2. The compound of formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof according to claim 1 , characterized in that the compound is:

N,N-dimethylaminosulfonyl-D-leucyl-L-prolyl-[(4-amidinophenyl)methyl]amide hydrochloride.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2024
From: LI, MIN
To: SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD.
Reel/Frame 067934/0881 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
To: LI, MIN
Reel/Frame 043117/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2015
From: SHAN, HANBIN; HUANG, YU; YUAN, ZHEDONG; YU, XIONG
To: LI, MIN; SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY
Reel/Frame 035809/0673 →
Priority Claims (1)
CN 2010 1 0535094 · Nov 8, 2010 · national
Continuity (1)
Related Publication 20130296245A1 · Nov 7, 2013